PTPA and prostate neoplasm: At 120 mg/kg administered orally, SH-BC-893 reduces nuclear MYC levels in tumors (Appendix Fig. S8B,C), disrupts PP2A-dependent trafficking (Kim et al, 2016; Finicle et al, 2023) and inhibits autochthonous prostate tumor growth by 82% (Kim et al, 2016).